SCHEMBL1423632

SCHEMBL1423632

CC(C)(C)OC(=O)N1CCN(CCCc2ccc(B3OC(C)(C)C(C)(C)O3)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 5/20 0.48
▸ LPL P06858 5/20 0.45
▸ LIPG Q9Y5X9 5/20 0.45
▸ USP30 Q70CQ3 1/20 0.45
▸ DRD2 P14416 1/20 0.43
▸ F2 P00734 1/20 0.43
▸ F11 P03951 1/20 0.43
▸ PRSS1 P07477 1/20 0.43
▸ PRSS2 P07478 1/20 0.43
▸ PRSS3 P35030 1/20 0.43
▸ HTR2A P28223 2/20 0.42
▸ OPRM1 P35372 2/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ ACKR3 P25106 2/20 0.42
▸ HTR1A P08908 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ TLR8 Q9NR97 1/20 0.41
▸ EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28327809 0.94 USP30 (0.46) SIGMAR1LPLLIPGUSP30F2
SCHEMBL3123517 0.87 USP30 (0.50) LPLLIPGUSP30
SCHEMBL21408919 0.86 USP30 (0.44) LPLLIPGUSP30F2F11
SCHEMBL19459152 0.83 EPHX2 (0.49) USP30DRD2HRH1EPHX2
SCHEMBL23753538 0.83 USP30 (0.48) LPLLIPGUSP30F2F11
SCHEMBL27391745 0.82 USP30 (0.52) LPLLIPGUSP30F2F11
SCHEMBL20294780 0.82 EPHX2 (0.48) USP30HRH1EPHX2
SCHEMBL28327826 0.82 LIPG (0.46) SIGMAR1LPLLIPGUSP30ACKR3
SCHEMBL1421344 0.80 SIGMAR1 (0.55) SIGMAR1DRD2HTR2AOPRM1ADORA3
SCHEMBL15997218 0.80 SIGMAR1 (0.55) SIGMAR1DRD2HTR2AOPRM1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2778156-B1 Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states ASTRAZENECA AB (SE) 2016-11-30 — — EP disclosed
EP-2778156-A1 Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states AstraZeneca AB (Publ) (SE) 2014-09-17 — — EP disclosed
US-8273774-B2 Phenoxypyridinylamide compounds ASTRAZENECA AB (SE) 2012-09-25 — — US disclosed
EP-2297106-A1 PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES AstraZeneca AB (SE) 2011-03-23 — — EP disclosed
US-20100041638-A1 Chemical Compounds 293 ASTRAZENECA AB (SE) 2010-02-18 — — US disclosed
WO-2009144494-A1 PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES ASTRAZENECA AB (SE) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041638-A1 Chemical Compounds 293 PDE4B, PDE4A, PDE3B SIGMAR1 4117/4885LPL 932/4885LIPG 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback